Biogen

An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.

Thursday, July 22, 2021 - 12:05pm

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) - On June 7, 2021, ADUHELM became the first approved treatment to address a defining pathology of Alzheimer’s disease: targeting the reduction of amyloid plaques in the brain. We believe patients, family members and physicians deserve the facts about the therapy and the process by which it was approved so they may make informed decisions.

Key Points: 
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • We are equally proud of the professionalism both our team and the FDA demonstrated during a thorough review process.
  • We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab.
  • The FDAs decision to approve ADUHELM to treat patients with Alzheimers disease was based on thorough analysis of the data.

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021

Wednesday, July 21, 2021 - 2:34am
Key Points: 
  • A poster presentation will also be given on the results of an in vivo study of E2511, Eisai's in-house discovered and developed investigational novel oral synapse regenerant.
  • Additionally, Eisai and Biogen Inc. (Nasdaq: BIIB) will hold a virtual symposium, "Defining the next-generation clinical care pathway for Alzheimer's disease: biological, technological, and healthcare perspectives," focusing on the AD treatment landscape.
  • Eisai serves as the lead in the co-development of lecanemab, an anti-Aβ protofibril antibody, which is being jointly developed by Eisai and Biogen.
  • Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia.

Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer

Wednesday, July 14, 2021 - 1:00pm

WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19th 2021.

Key Points: 
  • WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19th 2021.
  • Ms. Triola will be responsible for global commercial strategy, including U.S. sales and marketing operations.
  • Anna brings a distinctive set of commercial and leadership skills to Entasis, and a track record of commercializing products across multiple therapeutic areas, including antibacterials.
  • Prior to joining Summit, Ms. Triola held commercial leadership roles at Flexion Therapeutics, Chiasma, Cubist, and Biogen.

Initial Launch Execution Fails to Impress for Biogen's Aduhelm - the First-to-Market Disease-Modifying Therapy for the Treatment of Alzheimer's Disease - as the Controversy Churn Continues, According to Spherix Global Insights

Wednesday, July 14, 2021 - 12:45pm

Spherix initiated their Launch Dynamix: Aduhelm (Biogen) in Alzheimer's Disease (US) service immediately upon approval to provide clients with an ongoing, real-time assessment of the brand's launch and to capture vital benchmarking for potential future launches.

Key Points: 
  • Spherix initiated their Launch Dynamix: Aduhelm (Biogen) in Alzheimer's Disease (US) service immediately upon approval to provide clients with an ongoing, real-time assessment of the brand's launch and to capture vital benchmarking for potential future launches.
  • Surveyed neurologists anticipate that only one in seven Alzheimer's patients are considered candidates for Aduhelm.
  • Biogen, considered a powerhouse in the multiple sclerosis market, has not yet fueled comparable loyalty in the Alzheimer's market.
  • All company, brand or product names in this document are trademarks of their respective holders.

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

Tuesday, July 13, 2021 - 12:00am

For over 30 years, Biogen has led in MS research and today has a leading portfolio of MS products.

Key Points: 
  • For over 30 years, Biogen has led in MS research and today has a leading portfolio of MS products.
  • BTK inhibitors may have the potential to transform the treatment paradigm of autoimmune diseases, in particular MS.
  • Orelabrutinib is a small molecule Brutons tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases.
  • Among myeloid cells expressing BTK, microglia, which reside in the CNS, have been shown to express high level of BTK in multiple sclerosis.

Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease

Thursday, July 8, 2021 - 9:06pm

and NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Today, access to the worlds largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc.(Nasdaq: BIIB) and Pfizer (NYSE: PFE).

Key Points: 
  • and NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Today, access to the worlds largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc.(Nasdaq: BIIB) and Pfizer (NYSE: PFE).
  • These genetic data have been paired with detailed health information to create this browsable resource.
  • The collaboration between AbbVie, Biogen and Pfizer to make these data available highlights the importance of working together to advance science.
  • In line with the collaboration members commitment to openness, these results can now be accessed freely via the new browser.

FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials

Thursday, July 8, 2021 - 12:30pm

Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • The update clarifies the indication by emphasizing information about the disease stages studied in the ADUHELM clinical trials.
  • Information about the population studied has been previously communicated by Biogen and Eisai, including in the companies statement of June 23, 2021.
  • Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs

Thursday, July 1, 2021 - 1:00pm

Catalysts complement portfolio is led by the development candidates CB 4332 and CB 2782-PEG, originating from the companys internal discovery platform, which has generated a rich pipeline of leads.

Key Points: 
  • Catalysts complement portfolio is led by the development candidates CB 4332 and CB 2782-PEG, originating from the companys internal discovery platform, which has generated a rich pipeline of leads.
  • CB 4332 is an engineered CFI protease with the potential to become a therapy addressing multiple complement related disorders.
  • CB 2782-PEG is a potential best-in-class C3 degrader product candidate in preclinical development for the treatment of dry AMD that Catalyst has licensed to Biogen.
  • Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems.

Healthtech Solutions, Inc. Bolsters Management and Board with Two New Appointments

Thursday, July 1, 2021 - 1:00pm

Brad Mathis and Ryan Salomone have extensive backgrounds that make them uniquely positioned to bring substantial value to Healthtech.

Key Points: 
  • Brad Mathis and Ryan Salomone have extensive backgrounds that make them uniquely positioned to bring substantial value to Healthtech.
  • Brad Mathis brings a diversified skillset to Healthtech, acquired from over 30 years in the pharmaceutical and biotech industry.
  • Before joining Alexion, Brad held several positions of increasing responsibility with Amgen, Celgene, Biogen and BMS over a span of 15 years.
  • Ryans insights from developing the systematic investing approach at Twin Keel Capital will further bolster the evaluation and diligence processes at Healthtech.

Enel X Collaborates With Biogen To Electrify Take-home Vehicle Fleet In North America

Tuesday, June 29, 2021 - 1:53pm

and SAN CARLOS, Calif., June 29, 2021 /PRNewswire/ -- Enel X , the advanced energy services arm of the Enel Group, today announced it is working with Biogen Inc. (Nasdaq: BIIB) to electrify the global biotechnology company's employee commercial fleet.

Key Points: 
  • and SAN CARLOS, Calif., June 29, 2021 /PRNewswire/ -- Enel X , the advanced energy services arm of the Enel Group, today announced it is working with Biogen Inc. (Nasdaq: BIIB) to electrify the global biotechnology company's employee commercial fleet.
  • "Many of the world's largest companies are embracing the next major evolution in sustainability commitments by electrifying their fleets," said Giovanni Bertolino, Head of e-Mobility, Enel X North America.
  • Both Enel X and Biogen share commitments to 100% fleet electrification with aggressive targets.Enel, the parent company of Enel X, is committed to achieving complete decarbonization by 2050.
  • In North America, Enel X has around 4,500 business customers, spanning more than 35,000 sitesand representing approximately $10.5B in energy spend under management.